Drug intelligence / Profile preview

KF0113

Development stage: Preclinical
Modality: Small Molecules

Overview

KF0113 is a gold-based chemotherapeutic compound investigated for its cytotoxic activity on cancer cell lines, specifically A-498 renal carcinoma cells. It is structurally related to other gold-based compounds and has been studied for its effects on cell cycle disruption and apoptosis induction. Its mechanism of action is not fully elucidated but is presumed to involve interaction with cellular biomolecules and induction of cellular stress or apoptosis, similar to other gold-based agents.

Other names: KF1KF-1KF 1KF13KF-13KF 13

Beyond the preview

Go deeper on KF0113.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KF0113.

Explore the full profile